Practical approaches to laboratory assessment of risk of reсcurent thrombosis in antiphospholipid syndrome
https://doi.org/10.33667/2078-5631-2019-4-35(410)-16-22
Abstract
Antiphospholipid antibodies (aPLs) are a heterogenous group of auto‑ antibodies that interact with phospholipids (PL), phospholipid‑protein complexes and phospholipid‑binding proteins. aPLs are pathogenic and associated with the development of thrombosis and pregnancy pathology. The detection of aPLs as a diagnostic indicator is included in the criteria for antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) SLISS 2012. Also, aPLs is found in patients with other autoimmune, infectious diseases and cancer, in 10–12 % of elderly and 1–5 % healthy young people, but do not lead to the development of thrombosis and/or miscarriage. Simultaneous detection of aPLs with different tests indicate bad prognosis and a higher risk of clinical manifestation of APS. Triple positivity for classical markers of disease is found in patients with oncoming thrombosis. Another concept is the Global APS Score (GAPSS) that also takes into account the aPL profile as well as conventional cardiovascular risk factor and also some autoantibodies found in systemic disease. Currently, enzyme‑linked immunosorbent analysis (ELISA) are most widely used test for detection of aPLs. The advantage of new methods for detecting aPLs is to improve the parameters of sorption of antigens, automation, multiplex approach. Thus, new techniques can serve as a tool for the detection of aPLs and contribute to improving the quality of diagnosis of autoimmune diseases.
About the Authors
O. Yu. Tkachenko
First Saint Petersburg State Medical University n. a. I. P. Pavlov
Russian Federation
Russian Federation
Saint Petersburg
S. V. Lapin
First Saint Petersburg State Medical University n. a. I. P. Pavlov
Russian Federation
Russian Federation
Saint Petersburg
A. V. Mazing
First Saint Petersburg State Medical University n. a. I. P. Pavlov
Russian Federation
Russian Federation
Saint Petersburg
V. L. Emanuel
First Saint Petersburg State Medical University n. a. I. P. Pavlov
Russian Federation
Russian Federation
Saint Petersburg
References
1. Hughes G. R.V. Hughes Syndrome (the antiphospholipid syndrome) / Hughes G. R.V. // Autoimmunity Reviews — 2008. — V. 7 — N 3 — P. 262–266.
2. Wilson W. A. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop / Wilson W. A., Gharavi A. E., Koike T., Lockshin M. D., Branch D. W., Piette J.-C., Brey R., Derksen R., Harris E. N., Hughes G. R. V., Triplett D. A., Khamashta M. A. // Arthritis & Rheumatism — 1999. — V. 42 — N 7 — P. 1309–1311.
3. Miyakis S. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) / Miyakis S., Lockshin M. D., Atsumi T., Branch D. W., Brey R. L., Cervera R., Derkesen R. H.W.M., Groot P. G. De, Koike T., Meroni P. L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P. G., Krilis S. A. // Journal of Thrombosis and Haemostasis. — 2006. — V. 4 — N 2 — P. 295–306.
4. Pengo V. Antibody profiles for the diagnosis of antiphospholipid syndrome / Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. // Thrombosis and Haemostasis — 2005. — V. 93 — N 06 — P. 1147–1152.
5. Pengo V. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome / Pengo V., Ruffatti A., Legnani C., Gresele P., Barcellona D., Erba N., Testa S., Marongiu F., Bison E., Denas G., Banzato A., Padayattil Jose S., Iliceto S. // Journal of Thrombosis and Haemostasis — 2010. — V. 8 — N 2 — P. 237–242.
6. Tektonidou M. G. EULAR recommendations for the management of antiphospholipid syndrome in adults / Tektonidou M. G., Andreoli L., Limper M., Amoura Z., Cervera R., Costedoat-Chalumeau N., Cuadrado M. J., Dörner T., Ferrer-Oliveras R., Hambly K., Khamashta M. A., King J., Marchiori F., Meroni P. L., Mosca M., Pengo V., Raio L., Ruiz-Irastorza G., Shoenfeld Y., Stojanovich L., Svenungsson E., Wahl D., Tincani A., Ward M. M. // Annals of the Rheumatic Diseases — 2019. — DOI: 10.1136/annrheumdis-2019–215213
7. Otomo K. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events / Otomo K., Atsumi T., Amengual O., Fujieda Y., Kato M., Oku K., Horita T., Yasuda S., Koike T. // Arthritis and Rheumatism — 2012. — V. 64 — N 2 — V. 504–512.
8. Sciascia S. GAPSS: the Global Anti-Phospholipid Syndrome Score. / Sciascia S., Sanna G., Murru V., Roccatello D., Khamashta M. A., Bertolaccini M. L. // Rheumatology (Oxford, England) — 2013. — V. 52 — N 8 — P. 1397–403.
9. Meroni P. L. Pathogenesis of the antiphospholipid syndrome: An additional example of the mosaic of autoimmunity / Meroni P. L. // Journal of Autoimmunity — 2008. — V. 30 — N 1–2 — P. 99–103.
10. Meroni P.-L. Pathophysiology of the antiphospholipid syndrome (APS). / Meroni P.-L., Chighizola C. // La Revue de medecine interne — 2012. — Т. 33 Suppl 2 — P. A2–4.
11. Laat B. de Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change / Laat B. de // Blood — 2006. — V. 107 — N 5 — P. 1916–1924.
12. Ağar Ç. β2-Glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome / Ağar Ç., Os G. M.A. Van, Mörgelin M., Sprenger R. R., Marquart J. A., Urbanus R. T., Derksen R. H.W.M., Meijers J. C.M., Groot P. G. De // Blood — 2010. — V. 116 — N 8 — P. 1336–1343.
13. Misasi R. “New” Antigenic Targets and Methodological Approaches for Refining Laboratory Diagnosis of Antiphospholipid Syndrome / Misasi R., Capozzi A., Longo A., Recalchi S., Lococo E., Alessandri C., Conti F., Valesini G., Sorice M. // Journal of Immunology Research — 2015. — V. 2015 — P. 1–13.
14. Mahler M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome / Mahler M., Norman G. L., Meroni P. L., Khamashta M. // Autoimmunity Reviews — 2012. — V. 12 — N 2 — P. 313–317.
15. Cugno M. Patients with antiphospholipid syndrome display endothelial perturbation. / Cugno M., Borghi M. O., Lonati L. M., Ghiadoni L., Gerosa M., Grossi C., Angelis V. De, Magnaghi G., Tincani A., Mari D., Riboldi P., Meroni P. L. // Journal of autoimmunity — 2010. — V. 34 — N 2 — P. 105–10.
16. Boles J. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. / Boles J., Mackman N. // Lupus — 2010. — V. 19 — N 4 — P. 370–8.
17. Agostinis C. A non-complement-fixing antibody to 2 glycoprotein I as a novel therapy for antiphospholipid syndrome / Agostinis C., Durigutto P., Sblattero D., Borghi M. O., Grossi C., Guida F., Bulla R., Macor P., Pregnolato F., Meroni P. L., Tedesco F. // Blood — 2014. — V. 123 — N 22 — P. 3478–3487.
18. Pennings M. T.T. Interaction of β2-glycoprotein I with members of the low density lipoprotein receptor family / Pennings M. T.T., Lummel M. Van, Derksen R. H.W.M., Urbanus R. T., Romijn R. A., Lenting P. J., Groot P. G. De // Journal of Thrombosis and Haemostasis — 2006. — V. 4 — N 8 — P. 1680–1690.
19. Meroni P. L. Pathogenesis of antiphospholipid syndrome: understanding the antibodies / Meroni P. L., Borghi M. O., Raschi E., Tedesco F. // Nature Reviews Rheumatology — 2011. — V. 7 — N 6 — P. 330–339.
20. Simone N. Di Antiphospholipid Antibodies Affect Human Endometrial Angiogenesis1 / Simone N. Di, Nicuolo F. Di, D’Ippolito S., Castellani R., Tersigni C., Caruso A., Meroni P., Marana R. // Biology of Reproduction — 2010. — V. 83 — N 2 — P. 212–219.
21. Rand J. H. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: Role in pregnancy losses and thrombosis // Lupus. — 2010. — V. 19. — N 4. — P. 460–469.
22. Viall C. A. Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris / Viall C. A., Chen Q., Liu B., Hickey A., Snowise S., Salmon J. E., Stone P. R., Chamley L. W. // Journal of Autoimmunity — 2013. — V. 47 — P. 45–57.
23. Bertolaccini M. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010 / Bertolaccini M., Amengual O., Atsumi T., Binder W., Laat B. de, Forastiero R., Kutteh W., Lambert M., Matsubayashi H., Murthy V., Petri M., Rand J., Sanmarco M., Tebo A., Pierangeli S. // Lupus — 2011. — V. 20 — N 2 — P. 191–205.
24. Sater M. S. Anti-annexin V IgM and IgG autoantibodies and the risk of idiopathic recurrent spontaneous miscarriage / Sater M. S., Finan R. R., Mustafa F. E., Al-Khateeb G.M., Almawi W. Y. // Journal of Reproductive Immunology — 2011. — V. 89 — N 1 — P. 78–83.
25. Sciascia S. New Tests to Detect Antiphospholipid Antibodies: Antiprothrombin (aPT) and Anti-Phosphatidylserine/Prothrombin (aPS/ PT) Antibodies / Sciascia S., Khamashta M. A., Bertolaccini M. L. // Current Rheumatology Reports — 2014. — V. 16 — N 5 — P. 415.
26. Favaloro E. J. Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines / Favaloro E. J., Wong R. C.W. // Pathology — 2014. — V. 46 — N 6 — P. 481–495.
27. Erkan D. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends / Erkan D., Aguiar C. L., Andrade D., Cohen H., Cuadrado M. J., Danowski A., Levy R. A., Ortel T. L., Rahman A., Salmon J. E., Tektonidou M. G., Willis R., Lockshin M. D. // Autoimmunity Reviews — 2014. — V. 13 — N 6 — P. 685–696.
28. Branch D. W. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome / Branch D. W., Silver R., Pierangeli S., Leeuwen I. Van, Harris E. N. // Obstetrics and Gynecology — 1997.
29. Bertolaccini M. L. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome / Bertolaccini M. L., Roch B., Amengual O., Atsumi T., Khamashta M. A., Hughes G. R.V. // British Journal of Rheumatology — 1998.
30. Fialová L. Prevalence of various antiphospholipid antibodies in pregnant women / Fialová L., Mikulíková L., Matouš-Malbohan I., Benešová O., Zwinger A. // Physiological Research — 2000.
31. Katsuragawa H. Monoclonal Antibody against Phosphatidylserine Inhibits in Vitro Human Trophoblastic Hormone Production and Invasion1 / Katsuragawa H., Kanzaki H., Inoue T., Hirano T., Mori T., Rote N. S. // Biology of Reproduction — 1997. — V. 56 — N 1 — P. 50–58.
32. Gris J. C. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists Study — NOHA. / Gris J. C., Quéré I., Sanmarco M., Boutiere B., Mercier E., Amiral J., Hubert A. M., Ripart-Neveu S., Hoffet M., Tailland M. L., Rousseau O., Monpeyroux F., Dauzat M., Sampol J., Daures J. P., Berlan J., Marès P. // Thrombosis and haemostasis — 2000. — V. 84 — N 2 — P. 228–36.
33. Sugi T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-tolate pregnancy loss* / Sugi T., Matsubayashi H., Inomo A., Dan L., Makino T. // Journal of Obstetrics and Gynaecology Research — 2004. — V. 30 — N 4 — P. 326–332.
34. Sanmarco M. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis / Sanmarco M., Gayet S., Alessi M.-C., Audrain M., Maistre E. de, Gris J.-C., Groot P. de, Hachulla E., Harlé J.-R., Sié P., Boffa M.-C. // Thrombosis and Haemostasis — 2007. — V. 97 — N 06 — P. 949–954.
35. Sanmarco M. ELISA for antiphosphatidylethanolamine antibody detection: High impact of assay buffer on results / Sanmarco M. // Journal of Immunological Methods — 2010. — V. 358 — V. 1–2 — P. 9–16.
36. Ткаченко О. Ю. Сравнительный анализ иммунологических методов детекции антифосфолипидных антител / Ткаченко О. Ю., Лапин С. В., М М.А.В.Л.Н., Шмонин А. А., Соловьева Л. Н., Бондарева Е. А., Сельков С. А., Чепанов С. В., Тотолян А. А., Анализ С., Методов И. — 2017. — Т. 62 — № 1 — С. 40–44.
37. Capozzi A. Detection of antiphospholipid antibodies by automated chemiluminescence assay / Capozzi A., Lococo E., Grasso M., Longo A., Garofalo T., Misasi R., Sorice M. // Journal of Immunological Methods — 2012. — V. 379 — V. 1–2 — P. 48–52.
38. Noubouossie D. An automated chemiluminescence immunoassay may detect mostly relevant IgG anticardiolipin antibodies according to revised Sydney criteria. / Noubouossie D., Valsamis J., Corazza F., Rozen L., Debaugnies F., Demulder A. // Acta clinica Belgica — 2012.
39. Egerer K. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay / Egerer K., Roggenbuck D., Büttner T., Lehmann B., Kohn A., Landenberg P. von, Hiemann R., Feist E., Burmester G.-R., Dörner T. // Arthritis Research & Therapy — 2011. — V. 13 — N 4 — P. R 118.
40. Nalli C. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases / Nalli C., Somma V., Andreoli L., Büttner T., Schierack P., Mahler M., Roggenbuck D., Tincani A. // Autoimmunity Highlights — 2018. — V. 9 — N 1 — P. 6.
41. Ткаченко О. Ю., Лапин С. В., Шмонин А.А, Соловьева Л. Н., Бондарева Е. А., Сельков С. А., Чепанов С. В. Т.А.А. Анализ спектра антифосфолипидных антител у пациентов с тромбозами и привычным невынашиванием беременности / Ткаченко О. Ю., Лапин С. В., Шмонин А.А, Соловьева Л. Н., Бондарева Е. А., Сельков С. А., Чепанов С. В. Т.А.А., Дирк Р. // Medical Immunology (Russia) — 2018. — Т. 20 — № 5 — С. 753–762.
42. Roggenbuck D. Differentiation between APS patients and antiphospholipid antibody-positive carriers-impossible or matter of technique? / Roggenbuck D., Schierack P., Mahler M., P. Marcor, M. O. Borghi, Meroni P. L. // Clinical and Experimental Rheumatology — 2016.
Review
For citations:
Tkachenko O.Yu., Lapin S.V., Mazing A.V., Emanuel V.L. Practical approaches to laboratory assessment of risk of reсcurent thrombosis in antiphospholipid syndrome. Medical alphabet. 2019;4(35):16-22. (In Russ.) https://doi.org/10.33667/2078-5631-2019-4-35(410)-16-22
Views:
710
Email this article 